INS and fatty liver disease: In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1<sup>ΔHBS</sup> expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels.